6.10
0.03 (0.49%)
| Penutupan Terdahulu | 6.07 |
| Jumlah Dagangan | 4,322,893 |
| Harga / Jualan (P/S) | 12.41 |
| Harga / Buku (P/B) | 8.41 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Nuvation Bio Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.83 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 19.14% |
| % Dimiliki oleh Institusi | 62.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 30 Jun 2026 | 25,954,439 |
| Omega Fund Management, Llc | 30 Jun 2026 | 8,081,089 |
| Laurion Capital Management Lp | 30 Jun 2026 | 7,820,013 |
| Duquesne Family Office Llc | 30 Jun 2026 | 4,539,800 |
| Tang Capital Management Llc | 30 Jun 2026 | 3,299,557 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |